Building on these guidelines, extensive clinical trial and meta-analytic evidence underscores the efficacy of GLP-1 RAs in achieving significant weight reduction among adults with obesity, irrespective of diabetes status. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.